Drug Profile
Research programme: mucopolysaccharidosis IIIB therapy - Takeda
Alternative Names: HGT 3010Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Shire
- Class Enzymes
- Mechanism of Action Alpha N acetyl D glucosaminidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mucopolysaccharidosis III
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in Unknown (Intrathecal)
- 09 Feb 2012 Preclinical trials in Mucopolysaccharidosis III (Intrathecal)